Compare Amgen, Inc. (AMGN) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Beyond Meat Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Beyond Meat Inc trades at $0.66 (market cap $338.06M). The key difference: Amgen, Inc. is far larger — about 580.1× Beyond Meat Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| AMGN | BYND | |
|---|---|---|
Market Cap | $196.12B | $338.06M |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $4.28 |
52-Week Low | $271.18 | $0.52 |
Enterprise Value | $241.41B | $648.06M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BYND trades at $0.656, down 2.77% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a net income margin of 79.49% but negative operating cash flow of -$144.93M in 2025. Recent product expansions include Beyond Steak Filet at Meijer and Wegmans, while earnings have been volatile with two misses and one beat in the last four quarters.
The outlook remains challenging with 57% analyst sell ratings and declining revenue trends. Key risks include persistent cash burn and competitive pressures. Upside potential hinges on successful turnaround efforts through new product launches and cost management, but the stock faces significant headwinds near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
